Acumen Pharmaceuticals, Inc. (ABOS)

3.6300 -0.1000 (-2.68%) As of 02:36PM EDT. Market open.

Acumen Pharmaceuticals, Inc.

427 Park Street
Charlottesville, VA 22902
United States
434 297 1000
https://acumenpharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 51

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel J. O'Connell M.B.A.	CEO & Director	1.04M	N/A	1970
Mr. Matt Zuga	CFO & Chief Business Officer	702.6k	N/A	N/A
Mr. Derek M. Meisner Esq., J.D.	Chief Legal Officer & Corporate Secretary	752.95k	N/A	1971
Dr. James Doherty Ph.D.	President & Chief Development Officer	N/A	N/A	1968
Dr. Grant A. Krafft Ph.D.	Co-Founder	42k	N/A	N/A
Dr. Caleb E. Finch Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. William L. Klein Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Russell Barton M.S.	Chief Operating Officer	223.68k	N/A	1959
Ms. Kelly Carranza	Vice President, Finance & Accounting and Corporate Controller	N/A	N/A	N/A
Ms. Alex Braun M.B.A.	VP & Head of Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Corporate governance

Acumen Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.